"Etanercept" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant version of soluble human TNF receptor that binds specifically to TUMOR NECROSIS FACTOR and inhibits its binding with endogenous TNF receptors. It prevents the inflammatory effect of TNF and is used to treat RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS and ANKYLOSING SPONDYLITIS.
| Descriptor ID |
D000068800
|
| MeSH Number(s) |
D12.776.124.486.485.114.619.393.261 D12.776.124.790.651.114.619.393.261 D12.776.377.715.548.114.619.393.261 D12.776.543.750.705.852.760.232
|
| Concept/Terms |
TNFR-Fc Fusion Protein- TNFR-Fc Fusion Protein
- Fusion Protein, TNFR-Fc
- Protein, TNFR-Fc Fusion
- TNFR Fc Fusion Protein
- TNR-001
- TNR001
- TNR 001
- 001, TNR
- TNT Receptor Fusion Protein
- TNTR-Fc
|
Below are MeSH descriptors whose meaning is more general than "Etanercept".
Below are MeSH descriptors whose meaning is more specific than "Etanercept".
This graph shows the total number of publications written about "Etanercept" by people in this website by year, and whether "Etanercept" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etanercept" by people in Profiles.
-
Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF, Lapidus S, Perman MJ. Tumor necrosis factor-a inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. Pediatr Dermatol. 2019 Sep; 36(5):613-617.
-
Dehoratius RJ, Brent LH, Curtis JR, Ellis LA, Tang KL. Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. Patient. 2018 06; 11(3):361-369.
-
Huffstutter JE, Kafka S, Brent LH, Matucci-Cerinic M, Tang KL, Chevrier M, Sprabery T, DeHoratius RJ. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. Curr Med Res Opin. 2017 04; 33(4):657-666.
-
Bruminhent J, Lynch TK, Gefen J, Santoro J. Listeria monocytogenes cholecystitis: a possible new syndrome. Am J Med Sci. 2013 May; 345(5):414-7.
-
Holgate ST, Noonan M, Chanez P, Busse W, Dupont L, Pavord I, Hakulinen A, Paolozzi L, Wajdula J, Zang C, Nelson H, Raible D. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011 Jun; 37(6):1352-9.
-
Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis. J Clin Pharmacol. 2011 Jun; 51(6):864-75.
-
Fain JN, Nesbit AS, Sudlow FF, Cheema P, Peeples JM, Madan AK, Tichansky DS. Release in vitro of adipsin, vascular cell adhesion molecule 1, angiotensin 1-converting enzyme, and soluble tumor necrosis factor receptor 2 by human omental adipose tissue as well as by the nonfat cells and adipocytes. Metabolism. 2007 Nov; 56(11):1583-90.
-
Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J. 2000 Dec; 72(12):517-9.